Matthew S. Katz

Matthew S. Katz

Auto-generated profile, based on publicly available information

Matthew S. Katz

Department of Radiation Oncology, Tufts Medical Center

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PNPaul L. Nguyen
Paul L. Nguyen
ATAlphonse G. Taghian
Alphonse G. Taghian
MKMatthew S. Katz
Matthew S. Katz
ANAndrzej Niemierko
Andrzej Niemierko
RRRita F. Abi Raad
Rita F. Abi Raad
JHJay R. Harris
Jay R. Harris
Purpose: To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of lumpectomy and radiation therapy. Patients and Methods: We studied 793 consecutive patients with invasive breast cancer who received BCT from July 1998 to December 2001. Among them, 97% had pathologically negative margins of resection, and 90% received adjuvant systemic therapy. No patient received adjuvant trastuzumab. Receptor status was used to approximate subtype: estrogen receptor (ER) or progesterone receptor (PR) positive and human epidermal growth factor receptor 2 negative = luminal A; ER+ or PR+ and HER-2+ = luminal B; ER–and PR –and HER-2+ = HER-2; and ER–and PR –and HER-2–= basal. Competing risks methodology was used to analyze time to local recurrence and distant metastases. Results: Median follow-up was 70 months. The overall 5-year cumulative incidence of local recurrence was 1.8% (95% CI, 1.0 to 3.1); 0.8% (0.3, 2.2) for luminal A, 1.5% (0.2, 10) for luminal B, 8.4% (2.2, 30) for HER-2, and 7.1% (3.0, 16) for basal. On multivariable analysis (MVA) with luminal A as baseline, HER-2 (adjusted hazard ratio [AHR] = 9.2; 95% CI, 1.6 to 51; P = .012) and basal (AHR = 7.1; 95% CI, 1.6 to 31; P = .009) subtypes were associated with increased local recurrence. On MVA, luminal B (AHR = 2.9; 95% CI, 1.3 to 6.5; P = .007) and basal (AHR = 2.3; 95% CI, 1.1 to 5.2; P = .035) were associated with increased distant metastases. Conclusion: Overall, the 5-year local recurrence rate after BCT was low, but varied by subtype as approximated using ER, PR, and HER-2 status. Local recurrence was particularly low for the luminal A subtype, but was less than 10% at 5 years for all subtypes. Although further follow-up is needed, these results may be useful in counseling patients about their anticipated outcome after BCT.

17 March 2004 in JAMA
Verified
Journal Article
Open access
PDF file
ASAndrew J. Stephenson
Andrew J. Stephenson
SSShahrokh F. Shariat
Shahrokh F. Shariat
MZMichael J. Zelefsky
Michael J. Zelefsky
MKMichael W. Kattan
Michael W. Kattan
EBE. Brian Butler
E. Brian Butler
KSKevin M. Slawin
Kevin M. Slawin
Approximately 30 000 men annually in the United States will have recurrence of prostate cancer after radical prostatectomy.1 Initially, for most of these patients the only evidence of recurrent disease is an increasing serum prostate-specific antigen (PSA) level without radiographic or physical evidence of disease. An estimated 65% of these men will develop bone metastases within 10 years in the absence of salvage therapy.2 A rapid PSA doubling time (PSADT), high-grade disease, and a short disease-free interval after radical prostatectomy are prognostic factors associated with the development of metastases in untreated patients with an increasing PSA level.2-4 However, some patients with an increasing PSA level will have disease initially confined to the pelvis that subsequently may give rise to distant metastases. Isolated local relapse potentially can be cured by salvage radiotherapy, but there is no proven cure for metastatic disease.

1 February 2003 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMatthew S. Katz
Matthew S. Katz
MZMichael J. Zelefsky
Michael J. Zelefsky
EVEnnapadam S. Venkatraman
Ennapadam S. Venkatraman
ZFZvi Fuks
Zvi Fuks
AHAmanda Hummer
Amanda Hummer
SLSteven A. Leibel
Steven A. Leibel
Purpose: To identify predictors of biochemical outcome following radiotherapy in patients with a rising prostate-specific antigen (PSA) after radical prostatectomy for prostate cancer. Patients and Methods: One hundred fifteen patients with a rising PSA after radical prostatectomy received salvage three-dimensional conformal radiotherapy (3D-CRT) alone or with neoadjuvant androgen deprivation. Tumor-related and treatment-related factors were evaluated to identify predictors of subsequent PSA failure. Results: The median follow-up time after 3D-CRT was 42 months. The 4-year actuarial PSA relapse-free survival, distant metastasis-free survival, and overall survival rates were 46%, 83%, and 95%, respectively. Multivariate analysis, which was limited to 70 patients receiving radiation without androgen deprivation therapy, showed that negative/close margins (P = .03), absence of extracapsular extension (P < .01), and presence of seminal vesicle invasion (P < .01) were independent predictors of PSA relapse after radiotherapy. Neoadjuvant androgen deprivation did not improve the 4-year PSA relapse-free survival in patients with positive margins, extracapsular extension, and no seminal vesicle invasion (P = .24). However, neoadjuvant androgen deprivation did improve PSA relapse-free survival when one or more of these variables were absent (P = .03). Conclusions: Salvage 3D-CRT can provide biochemical control in selected patients with a rising PSA after radical prostatectomy. Among patients with positive margins and no poor prognostic features, 77% achieved PSA control after salvage 3D-CRT. Salvage neoadjuvant androgen deprivation therapy may improve short-term biochemical control, but it requires further study.

5 October 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Wasim AhmedWasim Ahmed
Wasim Ahmed
FSFrancesc López Seguí
Francesc López Seguí
Josep Vidal-AlaballJosep Vidal-Alaball
Josep Vidal-Alaball
MKMatthew S Katz
Matthew S Katz
Background: During the COVID-19 pandemic, a number of conspiracy theories have emerged. A popular theory posits that the pandemic is a hoax and suggests that certain hospitals are “empty.” Research has shown that accepting conspiracy theories increases the likelihood that an individual may ignore government advice about social distancing and other public health interventions. Due to the possibility of a second wave and future pandemics, it is important to gain an understanding of the drivers of misinformation and strategies to mitigate it. Objective: This study set out to evaluate the #FilmYourHospital conspiracy theory on Twitter, attempting to understand the drivers behind it. More specifically, the objectives were to determine which online sources of information were used as evidence to support the theory, the ratio of automated to organic accounts in the network, and what lessons can be learned to mitigate the spread of such a conspiracy theory in the future. Methods: Twitter data related to the #FilmYourHospital hashtag were retrieved and analyzed using social network analysis across a 7-day period from April 13-20, 2020. The data set consisted of 22,785 tweets and 11,333 Twitter users. The Botometer tool was used to identify accounts with a higher probability of being bots. Results: The most important drivers of the conspiracy theory are ordinary citizens; one of the most influential accounts is a Brexit supporter. We found that YouTube was the information source most linked to by users. The most retweeted post belonged to a verified Twitter user, indicating that the user may have had more influence on the platform. There was a small number of automated accounts (bots) and deleted accounts within the network. Conclusions: Hashtags using and sharing conspiracy theories can be targeted in an effort to delegitimize content containing misinformation. Social media organizations need to bolster their efforts to label or remove content that contains misinformation. Public health authorities could enlist the assistance of influencers in spreading antinarrative content.

1 February 2005 in Nature Clinical Practice Oncology
Verified
Journal Article
Closed access
MKMatthew S Katz
Matthew S Katz

1 March 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MKMatthew S. Katz
Matthew S. Katz
AUAudun Utengen
Audun Utengen
PAPatricia F. Anderson
Patricia F. Anderson
MTMichael A. Thompson
Michael A. Thompson
DADeanna J. Attai
Deanna J. Attai
DDDon S. Dizon
Don S. Dizon
Increasingly, patients, caregivers, and health care professionals (HCPs) go online to learn about and discuss cancer care.1 However, finding other people or organizations with similar interests can be difficult without some structure.